The Macular Photocoagulation Study (MPS) is a multicenter, collaborative, clinical trial that provides important guidelines for the treatment of choroidal neovascularization from age-related macular degeneration (AMD), presumed ocular histoplasmosis syndrome (POHS), and idiopathic neovascularization. In a previous editorial, Jampol1 discussed the role of hypertension among patients in the MPS, showing that under some circumstances, patients with hypertension had a less beneficial response to laser photocoagulation. Another aspect of the MPS that has received almost no attention to date is the racial characteristics of patients enrolled in the trial.
See also p 1701.
The MPS includes three clinical trials for AMD: argon-laser photocoagulation for extrafoveal membranes, krypton-laser photocoagulation for juxtafoveal membranes, and argon or krypton laser photocoagulation for subfoveal membranes. As of July 1,1991, a total of 1319 patients had been enrolled in these trials (Maureen Maguire, PhD, written communication). Of these patients, 1314 were white, one was black, and
Jampol LM, Tielsch J. Race, Macular Degeneration, and the Macular Photocoagulation Study. Arch Ophthalmol. 1992;110(12):1699-1700. doi:10.1001/archopht.1992.01080240039024